Page 47 - Priority Review News Today

The regulator Wednesday approved expanding Lonsurf’s label for previously treated metastatic colorectal cancer, authorizing a combination regimen with Roche’s bevacizumab.

Strong execution on strategic direction, delivering near-term value while charting a path for growth, exemplified by global partnership with Takeda Revenue grew 164% (173% CER) to US$533 million, with net income to

Strong execution on strategic direction, delivering near-term value while charting a path for growth, exemplified by global partnership with Takeda Revenue grew 164% to US$533 million, with net...

JEMPERLI is the first immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapyU.S. Food and Drug Administration approval represents a...

JEMPERLI is the first immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapyU.S. Food and...

By Chris Wack AnaptysBio shares were 11% higher after GSK received U.S. Food and Drug Administration approval for a treatment indication using a drug it licenses from AnaptysBio. The FDA...

Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy Patients with this type of endometrial cancer face...

A pill used for postpartum depression (PPD) is safe for use and has shown to be effective in managing symptoms, results of a new study has shown.PPD is a common perinatal complication experienced by one in eight women and has adverse maternal ...

Reports Second Quarter Revenues of $11.2 Billion Posts Second Quarter GAAP Earnings Per Share of $0.99 and Non-GAAP EPS of $1.75; Includes Net Impact of Per Share for GAAP and Non-GAAP EPS Due...

Investors.bms.com Second Quarter 2023 Earnings Highlights Second Quarter Highlights ...